The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
Open accessAbstract
BACKGROUND: Although health technology assessment (HTA) systems base their decision making process either on economic evaluations or comparative clinical benefit assessment, a central aim of recent approaches to value measurement, including value based assessment and pricing, points towards the incorporation of supplementary evidence and criteria that capture additional dimensions of value. OBJECTIVE: To study the practices, processes and policies of value-assessment for new medicines across eight European countries and the role of HTA beyond economic evaluation and clinical benefit assessment. METHODS: A systematic (peer review and grey) literature review was conducted using an analytical framework examining: (1) 'Responsibilities and structure of HTA agencies'; (2) 'Evidence and evaluation criteria considered in HTAs'; (3) 'Methods and techniques applied in HTAs'; and (4) 'Outcomes and implementation of HTAs'. Study countries were France, Germany, England, Sweden, Italy, Netherlands, Poland and Spain. Evidence from the literature was validated and updated through two rounds of feedback involving primary data collection from national experts. RESULTS: All countries assess similar types of evidence; however, the specific criteria/endpoints used, their level of provision and requirement, and the way they are incorporated (e.g. explicitly vs. implicitly) varies across countries, with their relative importance remaining generally unknown. Incorporation of additional 'social value judgements' (beyond clinical benefit assessment) and economic evaluation could help explain heterogeneity in coverage recommendations and decision-making. CONCLUSION: More comprehensive and systematic assessment procedures characterised by increased transparency, in terms of selection of evaluation criteria, their importance and intensity of use, could lead to more rational evidence-based decision-making, possibly improving efficiency in resource allocation, while also raising public confidence and fairness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6706 · Cited by 912
Claxton, K., Martin, S., Soares, M., Rice, N., Spackman, E., Hinde, S., Devlin, N., Smith, P. C., & Sculpher, M. (2015) · Health Technology Assessment · doi:10.3310/hta19140 · Cited by 853
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818
National Institute for Clinical Excellence and its value judgments
Rawlins, M. D., & Culyer, A. J. (2004) · BMJ · doi:10.1136/bmj.329.7459.224 · Cited by 765
Mauskopf, J. A., Sullivan, S. D., Annemans, L., Caro, J., Mullins, C. D., Nuijten, M., Orlewska, E., Watkins, J., & Trueman, P. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00187.x · Cited by 750
Weinstein, M. C., Torrance, G., & McGuire, A. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00515.x · Cited by 748
Thokala, P., Devlin, N., Marsh, K., Baltussen, R., Boysen, M., Kalo, Z., Longrenn, T., Mussen, F., Peacock, S., Watkins, J., et al. (2016) · Value in Health · doi:10.1016/j.jval.2015.12.003 · Cited by 739
Devlin, N., & Parkin, D. (2004) · Health Economics · doi:10.1002/hec.864 · Cited by 709
Anderson, J. L., Heidenreich, P. A., Barnett, P. G., Creager, M. A., Fonarow, G. C., Gibbons, R. J., Halperin, J. L., Hlatky, M. A., Jacobs, A. K., Mark, D. B., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000042 · Cited by 519
ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures
Anderson, J. L., Heidenreich, P. A., Barnett, P. G., Creager, M. A., Fonarow, G. C., Gibbons, R. J., Halperin, J. L., Hlatky, M. A., Jacobs, A. K., Mark, D. B., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.016 · Cited by 441
Clement, F. M., Harris, A., Li, J. J., Yong, K., Lee, K. M., & Manns, B. J. (2009) · JAMA · doi:10.1001/jama.2009.1409 · Cited by 343
The development of health technology assessment
Banta, D. (2003) · Health Policy · doi:10.1016/s0168-8510(02)00059-3 · Cited by 334
Marsh, K., Lanitis, T., Neasham, D., Orfanos, P., & Caro, J. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0135-0 · Cited by 276
Hughes-Wilson, W., Palma, A., Schuurman, A., & Simoens, S. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-74 · Cited by 170
Pharmacoeconomics: NICE's approach to decision-making
Rawlins, M., Barnett, D., & Stevens, A. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03589.x · Cited by 152 · cited 1×
“The existing influence of disease severity could be illustrated in the context of EoL treatments, where QALYs gained for terminal illnesses have a greater weight [95], on the grounds that society places a special value on extending the lives of the terminally ill [96].”
Background“Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-making
Dakin, H., Devlin, N. J., & Odeyemi, I. A. O. (2005) · Health Policy · doi:10.1016/j.healthpol.2005.08.008 · Cited by 143
The Members of the Italian Group for Pharmacoeconomic Studies, Capri, S., Ceci, A., Terranova, L., Merlo, D. F., & Mantovani, L. G. (2001) · Drug Information Journal · doi:10.1177/009286150103500122 · Cited by 123
Manchikanti, L., Falco, F. J. E., Boswell, M. V., & Hirsch, J. A. (2010) · Pain Physician · doi:10.36076/ppj.2010/13/e55 · Cited by 121
Golan, O. G., Hansen, P., Kaplan, G., & Tal, O. (2010) · Health Policy · doi:10.1016/j.healthpol.2010.10.012 · Cited by 102
Angelis, A., & Kanavos, P. G. (2016) · PharmacoEconomics · doi:10.1007/s40273-015-0370-z · Cited by 100
Self-citationThe ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report
McGhan, W. F., Al, M., Doshi, J. A., Kamae, I., Marx, S. E., & Rindress, D. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00605.x · Cited by 99
Operationalizing Value-Based Pricing of Medicines
Sussex, J., Towse, A., & Devlin, N. J. (2012) · PharmacoEconomics · doi:10.1007/s40273-012-0001-x · Cited by 98
The Common Drug Review: A NICE start for Canada?
McMahon, M., Morgan, S., & Mitton, C. (2005) · Health Policy · doi:10.1016/j.healthpol.2005.08.006 · Cited by 90
Cherny, N. I., Sullivan, R. J., Dafni, U. G., Kerst, J. M., Sobrero, A., Zielinski, C. C., de Vries, E. G. E., & Piccart, M. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw258 · Cited by 79
SIMILARITIES AND DIFFERENCES BETWEEN FIVE EUROPEAN DRUG REIMBURSEMENT SYSTEMS
Franken, M. G., Polain, M. L., Cleemput, I., & Koopmanschap, M. A. (2012) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462312000530 · Cited by 78
Priority setting in health policy in Sweden and a comparison with Norway
CALLTORP, J. (1999) · Health Policy · doi:10.1016/s0168-8510(99)00061-5 · Cited by 72
Dirksen, C. D., Utens, C. M. A., Joore, M. A., van Barneveld, T. A., Boer, B., Dreesens, D. H. H., van Laarhoven, H., Smit, C., Stiggelbout, A. M., & van der Weijden, T. (2013) · Implementation Science · doi:10.1186/1748-5908-8-64 · Cited by 70
An Ethical Analysis of International Health Priority-Setting
C, N. P. K. O., & Joffres, C. (2007) · Health Care Analysis · doi:10.1007/s10728-007-0065-5 · Cited by 68
Nicod, E., & Kanavos, P. G. (2015) · Health Policy · doi:10.1016/j.healthpol.2015.11.007 · Cited by 66
Self-citationKleijnen, S., GEORGE, E. L., Goulden, S., d’Andon, A., Vitré, P., Osińska, B., Rdzany, R. S., Thirstrup, S., Corbacho, B., Nagy, B. Z., et al. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.010 · Cited by 64
Reimbursement of pharmaceuticals: reference pricing versus health technology assessment
Drummond, M., Jönsson, B., Rutten, F., & Stargardt, T. (2010) · The European Journal of Health Economics · doi:10.1007/s10198-010-0274-y · Cited by 63
NICE's social value judgements about equity in health and health care
Shah, K. K., Cookson, R., Culyer, A. J., & Littlejohns, P. (2012) · Health Economics Policy and Law · doi:10.1017/s1744133112000096 · Cited by 61
Schubert, F. (2002) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462302000193 · Cited by 61
Schwarzer, R., & Siebert, U. (2009) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462309990092 · Cited by 60
Priority setting in the provincial health services authority: survey of key decision makers
Teng, F. F., Mitton, C., & MacKenzie, J. J. (2007) · BMC Health Services Research · doi:10.1186/1472-6963-7-84 · Cited by 56
Is quantitative benefit-risk modelling of drugs desirable or possible?
Phillips, L., Fasolo, B., Zafiropoulos, N., & Beyer, A. (2011) · Drug Discovery Today : Technologies · doi:10.1016/j.ddtec.2011.03.001 · Cited by 55
Persson, U., Willis, M. S., & Ödegaard, K. (2009) · The European Journal of Health Economics · doi:10.1007/s10198-009-0166-1 · Cited by 54
Rogowski, W. H., Hartz, S., & John, J. (2008) · BMC Health Services Research · doi:10.1186/1472-6963-8-194 · Cited by 51
Methods for the comparative evaluation of pharmaceuticals.
Zentner, A., Garrido, M. V., & Busse, R. (2005) · PubMed Central · Cited by 47
Decisions about access to health care and accountability for reasonableness
Daniels, N. (1999) · Journal of Urban Health · doi:10.1007/bf02344674 · Cited by 44
Centralized drug review processes: Are they fair?
Mitton, C., McMahon, M., Morgan, S., & Gibson, J. (2006) · Social Science & Medicine · doi:10.1016/j.socscimed.2005.11.049 · Cited by 44
Priority setting for pharmaceuticals
Anell, A. (2004) · The European Journal of Health Economics · doi:10.1007/s10198-003-0195-0 · Cited by 43
National Institute for Clinical Excellence (NICE): Is Economic Appraisal Working?
Towse, A., & Pritchard, C. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220003-00010 · Cited by 41
QALYs in cost-effectiveness analysis: an overview for cardiologists
Wouters, O. J., Naci, H., & Samani, N. J. (2015) · Heart · doi:10.1136/heartjnl-2015-308255 · Cited by 41
What criteria for pharmaceuticals reimbursement?
Pen, C. L., Priol, G., & Lilliu, H. (2003) · The European Journal of Health Economics · doi:10.1007/s10198-002-0145-2 · Cited by 37
The politics of health technology assessment in Poland
Ozierański, P., McKee, M., & KING, L. P. (2012) · Health Policy · doi:10.1016/j.healthpol.2012.10.001 · Cited by 34
Evidence and values: paying for end-of-life drugs in the British NHS
Chalkidou, K. (2012) · Health Economics Policy and Law · doi:10.1017/s1744133112000205 · Cited by 33
Blankart, K. E. (2012) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-12-83 · Cited by 29
Zschorlich, B., Knelangen, M., & Bastian, H. (2010) · Das Gesundheitswesen · doi:10.1055/s-0030-1261879 · Cited by 26
Pharmacoeconomics and Pharmacoepidemiology
Briggs, A. H., & Levy, A. R. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624110-00005 · Cited by 24
Trowman, R., Chung, H., Longson, C. M., Littlejohns, P., & Clark, P. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2510 · Cited by 23
Decision maker views on priority setting in the Vancouver Island Health Authority
Dionne, F., Mitton, C., Smith, N., et al. (2008) · Cost Effectiveness and Resource Allocation · doi:10.1186/1478-7547-6-13 · Cited by 23
Methods for determining cost-benefit ratios for pharmaceuticals in Germany
Schulenburg, J. ‐. G. V. D., Vauth, C., Mittendorf, T., & Greiner, W. (2007) · The European Journal of Health Economics · doi:10.1007/s10198-007-0063-4 · Cited by 21
Operationalising Value Based Pricing of Medicines: A Taxonomy of ApproachesPreprint
Sussex, J., Towse, A., & Devlin, N. J. (2015) · SSRN Electronic Journal · doi:10.2139/ssrn.2634410 · Cited by 21
Hoyle, M. (2010) · Value in Health · doi:10.1111/j.1524-4733.2010.00778.x · Cited by 19
Kaltenthaler, E., Boland, A., Carroll, C., Dickson, R., Fitzgerald, P., & Papaioannou, D. E. (2011) · Health Technology Assessment · doi:10.3310/hta15220 · Cited by 18
HTA responses and the classic HTA report
Milne, R., Clegg, A. J., & Stevens, A. J. (2003) · Journal of Public Health · doi:10.1093/pubmed/fdg023 · Cited by 14
Use of Economic Evaluation in Decision Making
Simoens, S. (2010) · Drugs · doi:10.2165/11538120-000000000-00000 · Cited by 9
Cited by
Report of the Lancet Commission on the Value of Death: Bringing death back into life
Sallnow, L., Smith, R., Ahmedzai, S. H., Bhadelia, A., Chamberlain, C., Cong, Y., Doble, B., Dullie, L., Durie, R., Finkelstein, E. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02314-x · Cited by 807
“216 These thresholds are typically presented in terms of the cost per quality adjusted life year (QALY) gained.”
Reason, T., Benbow, E., Langham, J., Gimblett, A., Klijn, S. L., & Malcolm, B. (2024) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00476-9 · Cited by 71
Characterizing attributes of innovation of technologies for healthcare: a systematic review
Syeed, M. S., Poudel, N., Ngorsuraches, S., Veettil, S. K., & Chaiyakunapruk, N. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2140591 · Cited by 18
Metadata
- Authors
- Angelis, A., Lange, A., & Kanavos, P.
- Venue
- The European Journal of Health Economics
- Published
- 2017-03-16
- Volume
- 19
- Issue
- 1
- Pages
- 123-152
- ISSN
- 1439-3972 (ISSN-L)
- 1618-7598
- 1618-7601
- OpenAlex
- W2596664472
- Cited by
- 305
- References
- 58
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.